ArticleArchives of osteoporosis2025
A nationwide study on the consumption and expenditure of osteoporosis medications in Iran during the period from 2001 to 2021.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Anti-osteoporosis medications (AOM) play a crucial role in the management of osteoporosis. The utilization of AOM in Iran has shown an overall increasing trend over time, albeit with fluctuations. However, underutilization is a fundamental challenge. Alendronate has consistently been the most widely used medication. PURPOSE: Anti-osteoporosis medications (AOM) play a crucial role in the management of osteoporosis. This study investigates the patterns of consumption and expenditures of these agents in Iran.
methodsThe wholesale data of the Iran Food and Drug Administration on the consumption and costs of AOM from 2001 to 2021 was investigated. Annual utilization of medications was converted to defined daily doses (DDDs) per 1000 individuals per day (DID). Adequacy of treatment was also calculated based on the proportion of post-menopausal patients who received a DDD per day of AOMs. Data were analyzed using descriptive statistics and Excel software.
resultsThe consumption and expenditure of AOM exhibited a fluctuation pattern. AOM utilization increased from 0.2 to 3.68 DID in 2021, indicating a rise of 19 times. Alendronate was consistently the most widely used medication, maintaining a share of > 90% from 2005 to 2015. With the increasing share of zoledronic acid and denosumab, the share of alendronate reduced in the last 5 years. In 2021, the AOM expenditure amounted to US$ 42.72 million purchasing power parities (PPP). In recent years, denosumab and teriparatide accounted for the majority of the expenditure. Majority of patients (84.25-97.54%) did not receive adequate treatment in the study period.
conclusionsThe utilization of AOM in Iran has shown an overall increasing trend over time, albeit with fluctuations. However, underutilization is a fundamental challenge. Given the impact of these medications on osteoporosis treatment and fracture reduction, it is imperative to identify patients and ensure timely and effective medication treatment.
Indexed as
Identifiers
41171491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.